Major depression is characterized as a debilitating, occasionally fatal disorder that may worsen the quality of life and well-being. 

Escitalopram has demonstrated a highly selective and dose-dependent inhibitory activity on human serotonin transport. Selective serotonin reuptake inhibitors (SSRIs) are approved to be the first-line drugs for managing major depressive disorder (MDD).

Thus a recent study explored the therapeutic potential of escitalopram in managing MDD and panic disorders by exploring the data of many reputed databases.

The results underscored the clinical efficacy, safety, recent development, increased bioavailability profile and stable formulation of escitalopram. Clinical and pharmacoeconomic data proved escitalopram to be an effective first-line treatment option for MDD patients.

These results regarding escitalopram are encouraging for further research perspectives.

Source: CNS & Neurological Disorders - Drug Targets, April 8, 2022.  DOI: https://doi.org/10.2174/1871527321666220301122807